华福证券就康方生物(9926.HK)发布研报称,该公司自研双抗AK112进度全球领先,有望占据全球二代IO市场的最大份额。预计公司2025-2027年营业收入分别为35.18/57.65/93.72亿元,归母净利润分别为-1.86/8.03/29.66亿元,合理市值为2228亿港元,维持买入评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.